Martin Sos - Publications

Affiliations: 
2011-2015 Cellular and Molecular Pharmacology University of California, San Francisco, San Francisco, CA 

46 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Fassunke J, Heydt C, Michels S, Van Veggel B, Müller F, Keul M, Dammert MA, Schmitt A, Smit EF, Kast S, Wolf J, Buettner R, Sos ML, Rauh D, Merkelbach-Bruse S. New insights into acquired resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor therapy in lung cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 30: ii51. PMID 32131274 DOI: 10.1093/annonc/mdz063.030  0.72
2019 Dammert MA, Brägelmann J, Olsen RR, Böhm S, Monhasery N, Whitney CP, Chalishazar MD, Tumbrink HL, Guthrie MR, Klein S, Ireland AS, Ryan J, Schmitt A, Marx A, Ozretić L, ... ... Sos ML, et al. MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer. Nature Communications. 10: 3485. PMID 31375684 DOI: 10.1038/s41467-019-11371-x  0.56
2018 Scheffler M, Ihle MA, Hein R, Merkelbach-Bruse S, Scheel AH, Siemanowski J, Brägelmann J, Kron A, Abedpour N, Ueckeroth F, Schüller M, Koleczko S, Michels S, Fassunke J, Pasternack H, ... ... Sos ML, et al. K-ras mutation subtypes in NSCLC and associated co-occuring mutations in other oncogenic pathways. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 30605727 DOI: 10.1016/j.jtho.2018.12.013  0.56
2018 Fassunke J, Müller F, Keul M, Michels S, Dammert MA, Schmitt A, Plenker D, Lategahn J, Heydt C, Brägelmann J, Tumbrink HL, Alber Y, Klein S, Heimsoeth A, Dahmen I, ... ... Sos ML, et al. Overcoming EGFR-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. Nature Communications. 9: 4655. PMID 30405134 DOI: 10.1038/s41467-018-07078-0  0.72
2017 Brägelmann J, Dammert MA, Dietlein F, Heuckmann JM, Choidas A, Böhm S, Richters A, Basu D, Tischler V, Lorenz C, Habenberger P, Fang Z, Ortiz-Cuaran S, Leenders F, Eickhoff J, ... ... Sos ML, et al. Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma. Cell Reports. 20: 2833-2845. PMID 28930680 DOI: 10.1016/j.celrep.2017.08.082  0.72
2017 Büttner R, Wolf J, Thomas RK, Sos ML. Resistance Mechanisms to AZD9291 and Rociletinib-Response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 23: 3967-3968. PMID 28710318 DOI: 10.1158/1078-0432.CCR-17-0948  0.56
2017 Malchers F, Ercanoglu MS, Schütte D, Castiglione R, Tischler V, Michels S, Dahmen I, Brägelmann J, Menon R, Heuckmann JM, George J, Ansén S, Sos ML, Soltermann A, Peifer M, et al. Mechanisms of primary drug resistance in FGFR1 amplified lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28630215 DOI: 10.1158/1078-0432.CCR-17-0478  0.56
2017 Plenker D, Riedel M, Brägelmann J, Dammert MA, Chauhan R, Knowles PP, Lorenz C, Keul M, Bührmann M, Pagel O, Tischler V, Scheel AH, Schütte D, Song Y, Stark J, ... ... Sos ML, et al. Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors. Science Translational Medicine. 9. PMID 28615362 DOI: 10.1126/scitranslmed.aah6144  0.56
2016 Mollaoglu G, Guthrie MR, Böhm S, Brägelmann J, Can I, Ballieu PM, Marx A, George J, Heinen C, Chalishazar MD, Cheng H, Ireland AS, Denning KE, Mukhopadhyay A, Vahrenkamp JM, ... ... Sos ML, et al. MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. Cancer Cell. PMID 28089889 DOI: 10.1016/j.ccell.2016.12.005  0.56
2016 Ortiz-Cuaran S, Scheffler M, Plenker D, Dahmen I, Scheel A, Fernandez-Cuesta L, Meder L, Lovly CM, Persigehl T, Merkelbach-Bruse S, Bos M, Michels S, Fischer R, Albus K, König K, ... ... Sos ML, et al. Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27252416 DOI: 10.1158/1078-0432.CCR-15-1915  0.56
2015 Costa HA, Leitner MG, Sos ML, Mavrantoni A, Rychkova A, Johnson JR, Newton BW, Yee MC, De La Vega FM, Ford JM, Krogan NJ, Shokat KM, Oliver D, Halaszovich CR, Bustamante CD. Discovery and functional characterization of a neomorphic PTEN mutation. Proceedings of the National Academy of Sciences of the United States of America. 112: 13976-81. PMID 26504226 DOI: 10.1073/pnas.1422504112  0.44
2015 Engel J, Richters A, Getlik M, Tomassi S, Keul M, Termathe M, Lategahn J, Becker C, Mayer-Wrangowski S, Grütter C, Uhlenbrock N, Krüll J, Schaumann N, Eppmann S, Kibies P, ... ... Sos ML, et al. Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach. Journal of Medicinal Chemistry. 58: 6844-63. PMID 26275028 DOI: 10.1021/acs.jmedchem.5b01082  0.56
2015 König K, Peifer M, Fassunke J, Ihle MA, Künstlinger H, Heydt C, Stamm K, Ueckeroth F, Vollbrecht C, Bos M, Gardizi M, Scheffler M, Nogova L, Leenders F, Albus K, ... ... Sos ML, et al. Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 26102443 DOI: 10.1097/JTO.0000000000000570  0.56
2015 Scheffler M, Merkelbach-Bruse S, Bos M, Fassunke J, Gardizi M, Michels S, Groneck L, Schultheis AM, Malchers F, Leenders F, Kobe C, König K, Heukamp LC, Sos ML, Thomas RK, et al. Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 10: e40-3. PMID 26001148 DOI: 10.1097/JTO.0000000000000503  0.56
2015 Gandara DR, Hammerman PS, Sos ML, Lara PN, Hirsch FR. Squamous cell lung cancer: from tumor genomics to cancer therapeutics. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2236-43. PMID 25979930 DOI: 10.1158/1078-0432.CCR-14-3039  0.56
2014 Sos ML, Levin RS, Gordan JD, Oses-Prieto JA, Webber JT, Salt M, Hann B, Burlingame AL, McCormick F, Bandyopadhyay S, Shokat KM. Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors. Cell Reports. 8: 1037-48. PMID 25127139 DOI: 10.1016/j.celrep.2014.07.010  0.44
2013 Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 503: 548-51. PMID 24256730 DOI: 10.1038/nature12796  0.44
2013 Lopez MS, Choy JW, Peters U, Sos ML, Morgan DO, Shokat KM. Staurosporine-derived inhibitors broaden the scope of analog-sensitive kinase technology. Journal of the American Chemical Society. 135: 18153-9. PMID 24171479 DOI: 10.1021/ja408704u  0.44
2013 Hertz NT, Berthet A, Sos ML, Thorn KS, Burlingame AL, Nakamura K, Shokat KM. A neo-substrate that amplifies catalytic activity of parkinson's-disease-related kinase PINK1. Cell. 154: 737-47. PMID 23953109 DOI: 10.1016/j.cell.2013.07.030  0.44
2013 Richters A, Ketzer J, Getlik M, Grütter C, Schneider R, Heuckmann JM, Heynck S, Sos ML, Gupta A, Unger A, Schultz-Fademrecht C, Thomas RK, Bauer S, Rauh D. Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design. Journal of Medicinal Chemistry. 56: 5757-72. PMID 23773153 DOI: 10.1021/jm4004076  0.56
2013 Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA, Garon EB, Dubinett SM, ... ... Sos ML, et al. Characteristics of lung cancers harboring NRAS mutations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2584-91. PMID 23515407 DOI: 10.1158/1078-0432.CCR-12-3173  0.56
2012 Sos ML, Dietlein F, Peifer M, Schöttle J, Balke-Want H, Müller C, Koker M, Richters A, Heynck S, Malchers F, Heuckmann JM, Seidel D, Eyers PA, Ullrich RT, Antonchick AP, et al. A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 109: 17034-9. PMID 23035247 DOI: 10.1073/pnas.1207310109  0.56
2012 Peifer M, Fernández-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, Plenker D, Leenders F, Sun R, Zander T, Menon R, Koker M, Dahmen I, Müller C, Di Cerbo V, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genetics. 44: 1104-10. PMID 22941188 DOI: 10.1038/ng.2396  0.56
2012 Heuckmann JM, Balke-Want H, Malchers F, Peifer M, Sos ML, Koker M, Meder L, Lovly CM, Heukamp LC, Pao W, Küppers R, Thomas RK. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 4682-90. PMID 22912387 DOI: 10.1158/1078-0432.CCR-11-3260  0.56
2012 Höpker K, Hagmann H, Khurshid S, Chen S, Hasskamp P, Seeger-Nukpezah T, Schilberg K, Heukamp L, Lamkemeyer T, Sos ML, Thomas RK, Lowery D, Roels F, Fischer M, Liebau MC, et al. AATF/Che-1 acts as a phosphorylation-dependent molecular modulator to repress p53-driven apoptosis. The Embo Journal. 31: 3961-75. PMID 22909821 DOI: 10.1038/emboj.2012.236  0.56
2012 Sos ML, Thomas RK. Genetic insight and therapeutic targets in squamous-cell lung cancer. Oncogene. 31: 4811-4. PMID 22266863 DOI: 10.1038/onc.2011.640  0.56
2011 Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, Brace LE, Woods BA, Lin W, Zhang J, Deng X, Lim SM, Heynck S, Peifer M, Simard JR, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discovery. 1: 78-89. PMID 22328973 DOI: 10.1158/2159-8274.CD-11-0005  0.56
2011 Park KS, Martelotto LG, Peifer M, Sos ML, Karnezis AN, Mahjoub MR, Bernard K, Conklin JF, Szczepny A, Yuan J, Guo R, Ospina B, Falzon J, Bennett S, Brown TJ, et al. A crucial requirement for Hedgehog signaling in small cell lung cancer. Nature Medicine. 17: 1504-8. PMID 21983857 DOI: 10.1038/nm.2473  0.56
2011 Heuckmann JM, Hölzel M, Sos ML, Heynck S, Balke-Want H, Koker M, Peifer M, Weiss J, Lovly CM, Grütter C, Rauh D, Pao W, Thomas RK. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 7394-401. PMID 21948233 DOI: 10.1158/1078-0432.CCR-11-1648  0.56
2011 Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R, Wang L, Amato KR, Arcila M, Sos ML, Socci ND, Viale A, de Stanchina E, Ginsberg MS, Thomas RK, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Science Translational Medicine. 3: 90ra59. PMID 21734175 DOI: 10.1126/scitranslmed.3002356  0.56
2011 Rode HB, Sos ML, Grütter C, Heynck S, Simard JR, Rauh D. Synthesis and biological evaluation of 7-substituted-1-(3-bromophenylamino)isoquinoline-4-carbonitriles as inhibitors of myosin light chain kinase and epidermal growth factor receptor. Bioorganic & Medicinal Chemistry. 19: 429-39. PMID 21130659 DOI: 10.1016/j.bmc.2010.11.007  0.72
2011 Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, Moch H, Wagener P, Fischer F, Heynck S, Koker M, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer (Science Translational Medicine (2011) 3) Science Translational Medicine. 3. DOI: 10.1126/scitranslmed.3002121  0.56
2010 Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, Moch H, Wagener P, Fischer F, Heynck S, Koker M, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Science Translational Medicine. 2: 62ra93. PMID 21160078 DOI: 10.1126/scitranslmed.3001451  0.56
2010 Pawar VG, Sos ML, Rode HB, Rabiller M, Heynck S, van Otterlo WA, Thomas RK, Rauh D. Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor. Journal of Medicinal Chemistry. 53: 2892-901. PMID 20222733 DOI: 10.1021/jm901877j  0.56
2010 Peifer M, Weiss J, Sos ML, Koker M, Heynck S, Netzer C, Fischer S, Rode H, Rauh D, Rahnenführer J, Thomas RK. Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling. Plos One. 5: e8919. PMID 20111714 DOI: 10.1371/journal.pone.0008919  0.56
2010 Sos ML, Rode HB, Heynck S, Peifer M, Fischer F, Klüter S, Pawar VG, Reuter C, Heuckmann JM, Weiss J, Ruddigkeit L, Rabiller M, Koker M, Simard JR, Getlik M, et al. Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Research. 70: 868-74. PMID 20103621 DOI: 10.1158/0008-5472.CAN-09-3106  0.56
2009 Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, Fröhling S, Chan EM, Sos ML, Michel K, Mermel C, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 462: 108-12. PMID 19847166 DOI: 10.1038/nature08460  0.56
2009 Sos ML, Thomas RK. Systematically linking drug susceptibility to cancer genome aberrations. Cell Cycle (Georgetown, Tex.). 8: 3652-6. PMID 19844167 DOI: 10.4161/cc.8.22.9936  0.56
2009 Sos ML, Fischer S, Ullrich R, Peifer M, Heuckmann JM, Koker M, Heynck S, Stückrath I, Weiss J, Fischer F, Michel K, Goel A, Regales L, Politi KA, Perera S, et al. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proceedings of the National Academy of Sciences of the United States of America. 106: 18351-6. PMID 19805051 DOI: 10.1073/pnas.0907325106  0.72
2009 Ocak S, Sos ML, Thomas RK, Massion PP. High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications. The European Respiratory Journal. 34: 489-506. PMID 19648524 DOI: 10.1183/09031936.00042409  0.56
2009 Sos ML, Michel K, Zander T, Weiss J, Frommolt P, Peifer M, Li D, Ullrich R, Koker M, Fischer F, Shimamura T, Rauh D, Mermel C, Fischer S, Stückrath I, et al. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. The Journal of Clinical Investigation. 119: 1727-40. PMID 19451690 DOI: 10.1172/JCI37127  0.56
2009 Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T, Seeger JM, Weiss J, Fischer F, Frommolt P, Michel K, Peifer M, Mermel C, Girard L, Peyton M, et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Research. 69: 3256-61. PMID 19351834 DOI: 10.1158/0008-5472.CAN-08-4055  0.56
2009 Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Getz G, Stefansson IM, Raeder MB, Sos ML, Engelsen IB, Trovik J, Wik E, Greulich H, Bø TH, Jonassen I, Thomas RK, et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proceedings of the National Academy of Sciences of the United States of America. 106: 4834-9. PMID 19261849 DOI: 10.1073/pnas.0806514106  0.56
2008 Ullrich RT, Zander T, Neumaier B, Koker M, Shimamura T, Waerzeggers Y, Borgman CL, Tawadros S, Li H, Sos ML, Backes H, Shapiro GI, Wolf J, Jacobs AH, Thomas RK, et al. Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET). Plos One. 3: e3908. PMID 19079597 DOI: 10.1371/journal.pone.0003908  0.56
2008 Sos ML, Zander T, Thomas RK, Staratschek-Jox A, Claasen J, Wolf J. Expression of signaling mediators downstream of EGF-receptor predict sensitivity to small molecule inhibitors directed against the EGF-receptor pathway. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 3: 170-3. PMID 18303439 DOI: 10.1097/JTO.0b013e3181622c05  0.56
2005 Thomas RK, Sos ML, Zander T, Mani O, Popov A, Berenbrinker D, Smola-Hess S, Schultze JL, Wolf J. Inhibition of nuclear translocation of nuclear factor-kappaB despite lack of functional IkappaBalpha protein overcomes multiple defects in apoptosis signaling in human B-cell malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 8186-94. PMID 16299251 DOI: 10.1158/1078-0432.CCR-05-0224  0.56
Show low-probability matches.